A new meta-analysis of six randomized controlled trials shows that lithium supplementation does not significantly slow cognitive decline in people with mild cognitive impairment or Alzheimers disease. While preclinical evidence suggests lithium supports resilience against amyloid and tau pathology, these benefits failed to translate to clinical outcomes using traditional lithium salts.
A new meta-analysis of six randomized controlled trials shows that lithium supplementation does not significantly slow cognitive decline in people with mild cognitive impairment or Alzheimers disease. While preclinical evidence suggests lithium supports resilience against amyloid and tau pathology, these benefits failed to translate to clinical outcomes using traditional lithium salts.
Share this Article
Recommended